Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mega Genomics Limited ( (HK:6667) ) has shared an update.
Mega Genomics Limited has announced a delay in the publication of its annual results for the year ended 31 December 2024, due to additional time required by auditors to assess revenue recognition and certain transactions. This delay has led to the postponement of the board meeting initially scheduled for 31 March 2025, and a suspension of trading, indicating potential compliance issues and operational impacts.
More about Mega Genomics Limited
Mega Genomics Limited is a company incorporated in the Cayman Islands, focusing on the genomics industry. It provides genetic testing kits and related services, operating within the market of genetic testing and biotechnology.
YTD Price Performance: -33.97%
Average Trading Volume: 111,860
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.63B
For a thorough assessment of 6667 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money